DLA Piper advised Brookline Capital in closing business combination with Apexigen
DLA Piper has advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its
DLA Piper advised Brookline Capital in closing business combination with Apexigen DLA Piper has advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its business combination with Apexigen Inc., a clinical-stage bio-pharmaceutical company. The combined publicly-traded company will now operate under the name Apexigen. Its common stock...
DLA Piper advised Brookline Capital in closing business combination with Apexigen
DLA Piper has advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its business combination with Apexigen Inc., a clinical-stage bio-pharmaceutical company.
The combined publicly-traded company will now operate under the name Apexigen. Its common stock commenced trading on the Nasdaq Capital Market under the ticker APGN
Apexigen focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company's pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, currently in Phase 2 clinical development. It also includes several preclinical stage immuno-oncology programs.
Jeffrey Selman, the Chair and Partner of DLA Piper's SPAC transactional practice led the firm's deal team. He said, "On behalf of our team, it was an honor working with Brookline Capital Acquisition and combining our SPAC M&A capabilities with our experience in the healthcare sector to support this transaction and Apexigen's future growth."
Samuel Wertheimer, the Chairman and CEO of Brookline Capital Acquisition Corp., remarked, "We are very pleased to have worked with the exceptional team at DLA Piper, led by Jeff Selman and James Kelly. Their guidance and focus were instrumental in the timely completion of this complex transaction, and for that we are thankful."
Meanwhile, James Kelly, the Head of DLA Piper's New York Private Equity practice, stated, "Congratulations to Brookline Capital Acquisition and Apexigen on this deal. This is a significant milestone for Apexigen as it continues to unlock innovative solutions in the oncology space. We are grateful to be a part of it."
The DLA Piper team also included partners Peter Ekberg (Minneapolis), Alan Seem, Carole Bellis (both in Silicon Valley) and Ilya Bubel (New York), and associates Spencer Hodson (Sacramento), Wei Li (Silicon Valley) and Peter Phillips (New York).
With over 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting them across all stages of development. The firm has been rated number one in global M&A volume for 12 consecutive years.
The firm's healthcare sector consists of a multi-disciplinary legal team with niche experience in health-related business and legal issues. The team works with corporations and financial institutions, private investors, private equity groups, venture capital funds, institutional investors and portfolio companies in all types of healthcare transactions.